Figure 1.Incidence of moderate-to-severe ({greater than or equal to}Grade 2) dermatologic adverse events within the first 12 weeks of first-line amivantamab plus lazertinib, with and without prophylactic dermatologic managementThe COCOON prophylaxis regimen halved the rate of significant skin AEs (38.6% vs. 76.5% with standard care). Bars show the percentage of patients in each arm experiencing any grade {greater than or equal to}2 dermatologic AE by week 12. Difference was statistically significant (p < 0.0001).
